Brazil's Hot New Drug Market Offers Challenges To Would-Be Entrants
This article was originally published in PharmAsia News
Brazil may be the new emerging-market darling of the pharmaceutical industry, but it failed to reach recently forecast growth levels because it offers a government system hard to crack.
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.